Associations Between Cardiac Autoantibodies and Changes in Arterial Stiffness in Youth with Type 1 Diabetes

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20240425006

Enrollment

Registered

2024-04-25

Start date

2024-04-17

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The prevalence of type 1 diabetes (T1D) in youth is rising globally. However, only 20-30% of children and adolescents with T1D achieve glycemic control, increasing their risk of long-term complications. The SEARCH study has shown that youth with T1D often have subclinical cardiovascular disease (CVD), evidenced by increased carotid intima media thickness and pulse wave velocity (PWV). This is likely due to a high prevalence of traditional CVD risk factors such as elevated body mass index, hypert

Interventions

Adolescents with type 1 diabetes per ADA criteria and positive for Islet cell antibodies, with variable glycemic controls

Diagnostic

Type 1 diabetes adolescent patients

Eligibility

Sex/Gender

All

Age

8 Years to 24 Years

Inclusion criteria

Inclusion criteria: 1.Diagnosed with type 1 diabetes per American Diabetes Association criteria, 2. Age at diagnosis equal or less than 18 years, 3. Diabetes duration of more than 1 year, 4. Regular follow up at Pediatric Diabetes Clinic, KKU hospital

Exclusion criteria

Exclusion criteria: 1. HbA1c more than 13%, 2. Creatinine more than 1.5 mg/dL, 3. Smoking, 4. Hypertension, 5. Receive medications that affect insulin resistance or arterial function, such as systemic/inhale glucocorticoids, oral antihyperglycemic drug, immunosuppressive drugs, and atypical antipsychotic drugs, in the 2 months, 5. Pregnancy, 6. Lactation, 7. Incomplete medical record, 8. Diabetic ketoacidosis in the past 2 months, 9. Other chronic illness affecting arterial function

Design outcomes

Primary

Measure	Time frame
Changes in carotid-femoral pulse wave velocity At 12-24 months carotid-femoral pulse wave velocity,Cardiac autoantibodies At baseline Cardiac autoantibodies: FL-MYH6, S2-MYH6, FL-MYH7	—

Secondary

Measure	Time frame
N-terminal pro-B type natriuretic peptide (NT-proBNP) At 3-6 months before the study serum NT-proBNP concentration	—

Countries

Thailand

Contacts

Public ContactPattara Wiromrat

Khon Kaen University

patwiro@kku.ac.th0867168485

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026